Madrigal Pharmaceuticals Inc EASL Investor Event Call Transcript
So thank you all for coming. And for those who have joined on the webcast, welcome. With me today, I have Dr. Becky Taub, President of R&D and Chief Medical Officer of Madrigal; and Stephen Harrison needs no introduction, lead investigator of our Phase III MAESTRO studies, resmetirom.
Please see today's press release, unless you want to memorize this for our forward-looking statements and I ask you to look at the press release today and our SEC filings for forward-looking statements and risk factor considerations associated with these statements and our business. The EASL 2022 International Liver Congress has been a busy time for Madrigal. Earlier today, we presented late-breaking data from our Phase III MAESTRO-NAFLD-1 safety study of resmetirom. This was the first presentation of the double-blind results in a major scientific meeting and we're going to review some of that data shortly. We and our collaborators presented 3 additional oral abstracts and 2 posters among the oral abstracts or analyses of new data from the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
